Clinical Trial Update: Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets) [Phase 1]

View source ↗

Summary

A Phase 1 food-effect bioavailability study of a fixed-dose combination of gemigliptin and metformin sustained-release (50/1000 mg total; 25/500 mg x 2 tablets)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Gemigliptin (gemigliptin)
• Metformin HCl sustained-release (Metformin)

Snippet

Sponsor: LG Life Sciences | Conditions: Type 2 Diabetes | Phase 1 | Status: COMPLETED